TAZORAC^® (tazarotene) Cream 0.1% is indicated for acne vulgaris.
TAZORAC^® (tazarotene) Gel 0.1% is indicated for mild to moderate facial acne vulgaris.

TAZORAC^® Cream and Gel 0.1% are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus.

TAZORAC^® Cream and Gel 0.1% are contraindicated in individuals who have shown hypersensitivity to any of its components.

Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC^® Cream or Gel 0.1% is used.

Retinoids should not be used on eczematous skin, as they may cause severe irritation.

TAZORAC^® Cream or Gel 0.1% should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity. Patients must be warned to use sunscreens (minimum SPF 15) and protective clothing when using TAZORAC^® Cream and Gel. Concomitant dermatologic agents that have a strong drying effect should be avoided.

The most frequent adverse reactions reported during clinical trials with TAZORAC^® Cream 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, dry skin, erythema, and burning sensation.

The most frequent adverse events reported with TAZORAC^® Gel 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, burning/stinging, dry skin, erythema, and pruritus.

Please click here for full prescribing information for TAZORAC^® Cream and Gel 0.1%.